<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165346</url>
  </required_header>
  <id_info>
    <org_study_id>CKNO-HEP-0703</org_study_id>
    <nct_id>NCT01165346</nct_id>
  </id_info>
  <brief_title>Stereotaxic Irradiation of Hepatocellular Carcinoma</brief_title>
  <acronym>CKNO-HEP</acronym>
  <official_title>Stereotaxic Irradiation of Hepatocellular Carcinoma : Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days for a total of 45 Gy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days for a total of 45 Gy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2009</start_date>
  <completion_date type="Actual">April 19, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>non-progression part</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Percentage of non-progression 18 months after treatment, according to RECIST criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute and late tolerance</measure>
    <time_frame>Up to 5 years after treatment</time_frame>
    <description>Evaluation of acute tolerance during 90 days after treatment and late tolerance after 90 days, according to NCI CTCAE v3.0 and RTOG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic non progression part</measure>
    <time_frame>Up to 3, 6, 9, 12 months</time_frame>
    <description>Percentage of hepatic non progression at 3, 6, 9, 12 months of treatment, according to RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median time without progression</measure>
    <time_frame>Up to 5 years after treatment</time_frame>
    <description>Time between :&#xD;
Date of inclusion&#xD;
Date of progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>Up to 5 years after treatment</time_frame>
    <description>determination of the best response of treatment, according to RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor evaluation</measure>
    <time_frame>Up to 5 years after treatment</time_frame>
    <description>According to EASL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Up to 18 months after treatment</time_frame>
    <description>Questionnaire EORTC QLQ-C30 and QLQ-HCC18</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological response</measure>
    <time_frame>Up to 3, 6, 9 months</time_frame>
    <description>tumoral marker : Alpha-fetoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical costs</measure>
    <time_frame>During the first 3 months</time_frame>
    <description>micro-costing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Stereotaxic radiation by CyberKnife</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of fiducials Stereotaxic radiation by CyberKnife : 3 X 15 Gy over 8 to 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fiducials</intervention_name>
    <description>Implantation of fiducials</description>
    <arm_group_label>Stereotaxic radiation by CyberKnife</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CyberKnife</intervention_name>
    <description>3 fractions over 8 to 10 days, 15 Gy/fraction</description>
    <arm_group_label>Stereotaxic radiation by CyberKnife</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primitive liver cancer (hepatocellular carcinoma), proved by histology or diagnostic&#xD;
             according to BCLC criteria&#xD;
&#xD;
          -  T1-3 N0 M0&#xD;
&#xD;
          -  With only one intra hepatic lesion and dimensions between 1 cm and 6 cm (IRM or&#xD;
             hepatic scanner)&#xD;
&#xD;
          -  Stereotaxic radiotherapy treatment approved in multidisciplinary consultation, the&#xD;
             patient being rejected for standard therapeutic&#xD;
&#xD;
          -  Age &gt;= 18 ans&#xD;
&#xD;
          -  Previous anti tumoral treatment allowed but suspended since at least 15 days before&#xD;
             the inclusion&#xD;
&#xD;
          -  OMS =&lt; 2&#xD;
&#xD;
          -  Portal thrombosis allowed&#xD;
&#xD;
          -  Portal high blood pressure allowed&#xD;
&#xD;
          -  No contraindication of fiducials implantation, hemostasis disorders must be treated&#xD;
             before the implantation&#xD;
&#xD;
          -  In case of underlying cirrhosis, only the Child-Pugh A is allowed&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  Women must have an active contraception during all the study&#xD;
&#xD;
          -  Patient affiliated to health insurance&#xD;
&#xD;
          -  Patient must sign the consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T4&#xD;
&#xD;
          -  Cirrhosis Child B and C&#xD;
&#xD;
          -  Hepatic lesion &lt; 1 cm or &gt; 6 cm&#xD;
&#xD;
          -  2 hepatic lesions or more&#xD;
&#xD;
          -  Recurrent or metastatic disease&#xD;
&#xD;
          -  Patient already included in another therapeutic trial with an experimental molecule&#xD;
&#xD;
          -  Allergy to gold&#xD;
&#xD;
          -  Pregnant women or susceptible to be pregnant or breastfeeding&#xD;
&#xD;
          -  Unable for medical follow-up (geographic, social or mental reasons)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier MIRABEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar LAMBRET</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 16, 2010</study_first_submitted>
  <study_first_submitted_qc>July 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2010</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver cancer</keyword>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

